Literature DB >> 14981718

Investigation of UBE3A and MECP2 in Angelman syndrome (AS) and patients with features of AS.

Megan P Hitchins1, Sarah Rickard, Fatima Dhalla, Una L Fairbrother, Bert B A de Vries, Robin Winter, Marcus E Pembrey, Sue Malcolm.   

Abstract

Angelman syndrome (AS) is an imprinted neurobehavioral disorder characterized by mental retardation, absent speech, excessive laughter, seizures, ataxia, and a characteristic EEG pattern. Classical lesions, including deletion, paternal disomy, or epigenetic mutation, are confirmatory of AS diagnoses in 80% of cases. Loss-of-function mutations of the UBE3A gene have been identified in approximately 8% of AS cases, failing to account for the remaining patient population, and there appears to be a higher prevalence of mutations in familial than sporadic cases. We screened UBE3A in 45 index cases of AS without obvious 15q11-13 abnormalities. Pathological mutations were identified in 3/6 (50%) familial and 4/39 (>10%) sporadic cases. By combining our data with those of the literature, we demonstrate statistically that the frequency of UBE3A mutations is significantly higher in the familial than sporadic subsets of AS. This indicates that an independent molecular mechanism or 'phenocopy' exists for the sporadic group. Rett syndrome (RS), caused by mutations of the MECP2 gene, and patients with deletions of 22q13.3 --> qter, have overlapping clinical features with AS. We screened 24 of the sporadic AS cases without detectable UBE3A mutations for mutations of MECP2, but found none. A separate cohort of 43 atypical patients with features common to AS and RS, in whom 15q11-13 lesions and 22q13.3 --> qter deletion had been ruled out, were also screened for MECP2 mutations. One male patient was mosaic for a frameshift mutation of this gene (previously reported). While MECP2 mutations can cause a phenotype reminiscent of AS in rare cases, they fail to account for the excess of sporadic patients with a definitive clinical diagnosis of AS. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981718     DOI: 10.1002/ajmg.a.20343

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  5 in total

Review 1.  MECP2 mutations in males.

Authors:  Laurent Villard
Journal:  J Med Genet       Date:  2007-03-09       Impact factor: 6.318

2.  Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome.

Authors:  J L Neul; P Fang; J Barrish; J Lane; E B Caeg; E O Smith; H Zoghbi; A Percy; D G Glaze
Journal:  Neurology       Date:  2008-03-12       Impact factor: 9.910

Review 3.  Immunologic and neurodevelopmental susceptibilities of autism.

Authors:  Isaac N Pessah; Richard F Seegal; Pamela J Lein; Janine LaSalle; Benjamin K Yee; Judy Van De Water; Robert F Berman
Journal:  Neurotoxicology       Date:  2008-02-23       Impact factor: 4.294

4.  Parent report of stereotyped behaviors, social interaction, and developmental disturbances in individuals with Angelman syndrome.

Authors:  Nicolay Chertkoff Walz
Journal:  J Autism Dev Disord       Date:  2007-05

5.  Familial cases and male cases with MECP2 mutations.

Authors:  Qingping Zhang; Ying Zhao; Xinhua Bao; Jinjun Luo; Xiaoying Zhang; Jiarui Li; Liping Wei; Xiru Wu
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-04-10       Impact factor: 3.568

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.